Compare RPID & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPID | ONCY |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.6M | 107.3M |
| IPO Year | 2021 | 2002 |
| Metric | RPID | ONCY |
|---|---|---|
| Price | $2.11 | $0.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $8.00 | $7.33 |
| AVG Volume (30 Days) | 218.3K | ★ 1.5M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,587,000.00 | N/A |
| Revenue This Year | $19.12 | N/A |
| Revenue Next Year | $18.42 | $2,505.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.74 | N/A |
| 52 Week Low | $1.66 | $0.73 |
| 52 Week High | $4.94 | $1.51 |
| Indicator | RPID | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 56.29 | 35.51 |
| Support Level | $1.98 | N/A |
| Resistance Level | $2.17 | $1.06 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 61.11 | 1.97 |
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.